The historical rank and industry rank for Infant Bacterial Therapeutics AB's EV-to-FCF or its related term are showing as below:
FRA:9IB'
s EV-to-FCF Range Over the Past 10 Years
Min: -55.86 Med: -8.66 Max: 8.02
Current: -12.48
During the past 12 years, the highest EV-to-FCF of Infant Bacterial Therapeutics AB was 8.02. The lowest was -55.86. And the median was -8.66.
FRA:9IB's EV-to-FCF is ranked worse than 100% of 332
companies
in the Biotechnology industry
Industry Median: 16.26
vs FRA:9IB: -12.48
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Infant Bacterial Therapeutics AB (FRA:9IB) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Infant Bacterial Therapeutics AB's PE Ratio (TTM) for today is calculated as:
Infant Bacterial Therapeutics AB's share price for today is €6.29.
Infant Bacterial Therapeutics AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.486.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Infant Bacterial Therapeutics AB EV-to-FCF Related Terms
Infant Bacterial Therapeutics AB EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Infant Bacterial Therapeutics AB's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Infant Bacterial Therapeutics AB EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Infant Bacterial Therapeutics AB's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Infant Bacterial Therapeutics AB's EV-to-FCF falls into.
Infant Bacterial Therapeutics AB's current Enterprise Value is €73.06 Mil.
Infant Bacterial Therapeutics AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-5.20 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Infant Bacterial Therapeutics AB (FRA:9IB) has a EV-to-FCF of -14.04 as of Jul. 04, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Infant Bacterial Therapeutics AB and its competitors. According to the industry distribution chart, Infant Bacterial Therapeutics AB ranks #999999 out of 332 companies in the Biotechnology industry.
Is Infant Bacterial Therapeutics AB's EV-to-FCF too high?
Infant Bacterial Therapeutics AB's current EV-to-FCF is -14.04. Based on the distribution chart, Infant Bacterial Therapeutics AB ranks #999999 out of 332 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Infant Bacterial Therapeutics AB has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Infant Bacterial Therapeutics AB's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Infant Bacterial Therapeutics AB ranks #999999 out of 332 companies for EV-to-FCF. This places Infant Bacterial Therapeutics AB in the lower half of its industry. The industry median EV-to-FCF is 16.26. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.26, based on 332 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Infant Bacterial Therapeutics AB and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Infant Bacterial Therapeutics AB's current EV-to-FCF is -14.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Infant Bacterial Therapeutics AB stock overvalued right now?
Infant Bacterial Therapeutics AB (FRA:9IB) has a current EV-to-FCF of -14.04. The current EV-to-FCF is -14.04. Infant Bacterial Therapeutics AB's overall GF Score™ is 13/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Infant Bacterial Therapeutics AB (FRA:9IB), the current EV-to-FCF is -14.04 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Infant Bacterial Therapeutics AB Business Description
Infant Bacterial Therapeutics AB is a pharmaceutical company. Its purpose is to develop and commercialize drugs for diseases affecting premature babies. Its focus is on the drug candidate IBP-9414, whose development program is designed to show a reduced incidence of necrotizing enterocolitis (NEC) and improved gastrointestinal function (SFT) when treated with IBP-9414's active substance, Lactobacillus reuteri bacterial strain naturally found in human breast milk. Its portfolio also includes additional drug candidates, IBP-1016, IBP-1118, and IBP-1122. IBP1016, for the treatment of gastroschisis, is a life-threatening and rare disorder in which children are born with externalized gastrointestinal organs.
13GF Score
Get the complete analysis for FRA:9IB
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:9IB has been successfully added to your 
